Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
162.20B
Market cap162.20B
Price-Earnings ratio
10.58
Price-Earnings ratio10.58
Dividend yield
3.34%
Dividend yield3.34%
Average volume
17.38M
Average volume17.38M
High today
$36.44
High today$36.44
Low today
$35.60
Low today$35.60
Open price
$37.15
Open price$37.15
Volume
715.80K
Volume715.80K
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.60
52 Week low$35.60

NVO News

Bloomberg 7h
Novo Chairman Faces Testy Investors With Little Progress So Far

Novo Nordisk A/S’s Chairman Lars Rebien Sorensen will face investors at the company’s annual meeting for the first time on Thursday after his boardroom coup. He...

Novo Chairman Faces Testy Investors With Little Progress So Far
Simply Wall St 11h
Novo Nordisk’s Recent Momentum Shift Prompts Fresh Look At Valuation Gap

Advertisement How Novo Nordisk’s recent performance sets up the current valuation debate Novo Nordisk (NYSE:NVO) has recently seen weak share price performanc...

Novo Nordisk’s Recent Momentum Shift Prompts Fresh Look At Valuation Gap
Nasdaq 20h
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data

Novo Nordisk NVO and its partner, The United Laboratories International Holdings Limited ("TUL"), jointly announced top-line data from a phase II study in China...

NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data

Analyst ratings

60%

of 35 ratings
Buy
31.4%
Hold
60%
Sell
8.6%

More NVO News

Benzinga 23h
Is Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?

Semaglutide is a key ingredient in the famed Wegovy and Ozempic. UBT251 Shows Superior Glycemic Control And Weight Loss The once-weekly injectable UBT251 targ...

Is Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?
Nasdaq 2d
Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer

Key Points Regulators recently approved Wegovy HD, which is a higher-dose version of its popular weight loss drug. Wegovy HD helped people lose 20.7%, on aver...

Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer
Nasdaq 3d
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?

Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader in the GLP-1 space, Novo Nordisk ma...

NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
TipRanks 3d
Novo Nordisk Advances DKK 15 Billion Share Buyback, Holds 0.6% in Treasury Shares

The latest update is out from Novo Nordisk ( (NVO) ). Novo Nordisk has been executing a significant share repurchase programme as part of its capital allocatio...

TipRanks 3d
Lexicon, Novo Nordisk announce initiation of LX9851 study

Lexicon (LXRX) and Novo Nordisk (NVO) announced that Novo Nordisk has initiated a Phase 1 study with LX9851, an oral non-incretin development candidate. In Marc...

Simply Wall St 3d
Can Hims & Hers Turn Novo Nordisk Truce And New CCO Hire Into Lasting Brand Advantage?

Earlier in March 2026, Hims & Hers Health announced that Kathryn Beiser, a veteran of Discover, Kaiser Permanente, Eli Lilly, and Edelman, had joined as Chief C...

Can Hims & Hers Turn Novo Nordisk Truce And New CCO Hire Into Lasting Brand Advantage?
Simply Wall St 4d
A Look At Hims & Hers Health Valuation After Novo Nordisk Renews Weight Loss Drug Partnership

The sharp recent move in Hims & Hers Health (HIMS) comes after Novo Nordisk agreed to resume selling its weight loss drugs on the platform, ending a public lega...

A Look At Hims & Hers Health Valuation After Novo Nordisk Renews Weight Loss Drug Partnership

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.